Nathan.qxp 29/7/08 10:07 Page 21
Non-ST-segment Elevation Acute Coronary Syndromes
Conclusion of the condition, risk stratification, early implementation of optimal
In summary, the management of NSTE-ACS has progressed greatly in recent pharmacological therapies, and appropriate use of invasive diagnostics
years but there is still considerable room for improvement. Current US and therapeutics. Targeted pharmacotherapy and prompt mechanical
estimates suggest that only 12% of NSTE-ACS patients receive all revascularization generally yield the best clinical outcomes in high-risk patients.
guideline-recommended therapies within the first 48 hours.
Other Efforts to improve the process and quality of ACS care should continue on
investigators note that evidence-based therapies paradoxically target individual, institutional, and national levels. Adoption of structured, evidence-
low-risk patients despite evidence suggesting their greatest benefit based treatment strategies is essential for insuring optimal patient outcomes in
in higher-risk patients.
The goals of ACS management are rapid identification this rapidly evolving sector of cardiovascular medicine. ■
1. Anderson JL, Adams CD, Antman EM, et al., ACC/AHA 2007 19. de Winter RJ, Windhausen F, Cornel JH, et al., Early invasive versus death, myocardial infarction, and stroke in high-risk patients, BMJ,
Guidelines for the Management of Patients With Unstable selectively invasive management for acute coronary syndromes, 2002;324:71–86.
Angina/Non-ST-elevation Myocardial Infarction, J Am Coll Cardiol, N Engl J Med, 2005;353:1095–1104. 37. Yusuf S, Zhao F, Mehta SR, et al., Effects of clopidogrel in addition
2007;50:e1–157. 20. Mehta SR, Cannon CP, Fox KA, et al., Routine versus selective to aspirin in patients with acute coronary syndromes without
2. Bassand JP, Hamm CW, Ardissino D, et al., Guidelines for the invasive strategies in patients with acute coronary syndromes: A ST-segment elevation, N Engl J Med, 2001;345:494–502.
diagnosis and treatment of non-ST-segment elevation acute collaborative meta-analysis of randomized trials, JAMA, 2005;293: 38. Mehta SR, Yusuf S, Peters RJG, et al., Effects of pre-treatment with
coronary syndromes. The Task Force for the Diagnosis and 2908–17. clopidogrel and aspirin followed by long-term therapy in patients
Treatment of Non-ST-Segment Elevation Acute Coronary 21. Hoenig MR, Doust JA, Aroney CN, et al., Early invasive versus undergoing percutaneous coronary intervention: the PCI-CURE
Syndromes of the European Society of Cardiology, Eur Heart J, conservative strategies for unstable angina and non–ST-elevation study, Lancet, 2001;358:527–33.
2007;28:1598–1660. myocardial infarction in the stent era, Cochrane Database Syst Rev, 39. Montalescot G, Sideris G, Meuleman C, et al., A randomized
3. Roe MT, Parsons LS, Pollack CV, et al., Quality of care by 2006;CD004815. comparison of high clopidogrel loading doses in patients with
classification of myocardial infarction, Arch Intern Med, 22. Bavry AA, Kumbhani DJ, Rassi AN, et al., Benefit of early invasive non–ST-segment elevation acute coronary syndromes. The
2005;165:1630–36. therapy in acute coronary syndromes, J Am Coll Cardiol, Assessment of the Best Loading Dose of Clopidogrel to Blunt
4. Taneja AK, Collinson J, Flather MD, et al., Mortality following 2006;48:1319–25. Platelet Activation, Inflammation and Ongoing Necrosis (ALBION)
non-ST elevation acute coronary syndrome: four years follow-up of 23. Ryan JW, Peterson ED, Chen AY, et al., Optimal timing of Trial, J Am Coll Cardiol, 2006;48:931–8.
the PRAIS UK Registry (Prospective Registry of Acute Ischaemic intervention in non-ST-segment elevation acute coronary 40. Patti G, Collona G, Pasceri V, et al., Randomized trial of high
Syndromes in the UK), Eur Heart J, 2004;25:2013–18. syndrome, Circulation, 2005;112:3049–57. loading dose of clopidogrel for reduction of periprocedural
5. Savonitto S, Ardissino D, Granger CB, et al., Prognostic value of 24. Boden WE, Shah PK, Gupta V, et al., Contemporary approach to myocardial infarction in patients undergoing coronary
the admission electrocardiogram in acute coronary syndromes, the diagnosis and management of non-ST-segment elevation intervention, Circulation, 2005;111:2099–2106.
JAMA, 1999;281:707–13. acute coronary syndromes, Prog Cardiovasc Dis, 2008;50:311–51. 41. Von Beckerath N, Taubert D, Pogatsa-Murray G, et al., Absorption,
6. Libby P, Current concepts of the pathogenesis of the acute 25. Peterson ED, Roe MT, Mulgund J, et al., Association between metabolization, and antiplatelet effects of 300, 600, and 900mg
coronary syndromes, Circulation, 2001;104:365–72. hospital process performance and outcomes among patients with loading doses of clopidogrel, Circulation, 2005;112:2946–50.
7. Shah PK, Mechanisms of plaque vulnerability and rupture, J Am acute coronary syndromes, JAMA, 2006;295:1912–20. 42. Nguyen TA, Diodati JG, Pharand C, Resistance to clopidogrel: A
Coll Cardiol, 2003;41(Suppl. 4):15–22S. 26. Oler A, Whooley MA, Oler J, et al., Adding heparin to aspirin review of the evidence, J Am Coll Cardiol, 2005;45:1157–64.
8. Brummel KE, Paradis SG, Butenas Saulius, et al., Thrombin reduces the incidence of myocardial infarction and death in 43. Wiviott SD, Braunwald E, McCAbe CH, et al., Prasugrel versus
functions during tissue factor-induced blood coagulation, Blood, patients with unstable angina. A meta-analysis, JAMA, clopidogrel in patients with acute coronary syndromes, N Engl J
2002;100:145–52. 1996;276:811–15. Med, 2007;357:2001–15.
9. Monroe DM, Hoffman M, What Does it Take to Make the Perfect 27. Petersen JL, Mahaffey KW, Hasselblad V, et al., Efficacy and 44. Bhatt DL, Topol EJ, Current role of platelet glycoprotein IIb/IIIa
Clot?, Arterioscler Thromb Vasc Biol, 2006;26:41–8. bleeding complications among patients randomized to enoxaparin inhibitors in acute coronary syndromes, JAMA, 2000;284:
10. Rioufol G, Finet G, Ginon I, et al., Multiple atherosclerotic plaque or unfractionated heparin for antithrombin therapy in 1549–58.
rupture in acute coronary syndrome. A three-vessel intravascular non-ST-segment elevation acute coronary syndromes, JAMA, 45. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet
ultrasound study, Circulation, 2002;106:804–8. 2004;292:89–96. glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A
11. Steg PG, Bhatt DL, Wilson PW, et al., REACH Registry 28. Ferguson JJ, Califf RM, Antman EM, et al., Enoxaparin versus meta-analysis of all major randomised clinical trials, Lancet,
Investigators. One-year cardiovascular event rates in outpatients unfractionated heparin in high-risk patients with non-ST-segment 2002;359:189–98.
with atherothrombosis, JAMA, 2007;297:1197–1206 elevation acute coronary syndromes managed with an intended 46. Roffi M, Chew DP, Mukherjee D, et al., Platelet glycoprotein IIb/IIIa
12. Antman EM, Cohen M, Bernink PJ, et al., The TIMI risk score for early invasive strategy, JAMA, 2004;292:45–54. inhibitors reduce mortality in diabetic patients with
unstable angina/non–ST-elevation MI, JAMA, 2000;284:835–42. 29. Alexander KP, Chen AY, Roe MT, et al., Excess dosing of non-ST-segment-elevation acute coronary syndromes, Circulation,
13. Granger CB, Goldberg RJ, Dabbous O, et al., Predictors of hospital antiplatelet and antithrombin agents in the treatment of 2001;104:2767–71.
mortality in the global registry of acute coronary events, non-ST-segment elevation acute coronary syndromes, JAMA, 47. Kong DF, Hasselblad V, Harrington RA, et al., Meta-analysis of
Arch Intern Med, 2003;163:2345–53. 2005;294:3108–16. survival with platelet glycoprotein IIb/IIIa antagonists for
14. Boersma E, Pieper KS, Steyerberg EW, et al., Predictors of outcome 30. Di Nisio M, Middeldorp S, Buller HR, Direct thrombin inhibitors, percutaneous coronary interventions, Am J Cardiol, 2003;92:
in patients with acute coronary syndromes without persistent N Engl J Med, 2005;353:1028–40. 651–5.
ST-segment elevation. Results from an international trial of 9,461 31. Stone GW, McLaurin BT, Cox DA, et al., Bivalirudin for patients 48. Harrington RA, Becker RC, Cannon CP, et al., Antithrombotic
patients. The PURSUIT Investigators, Circulation, 2000;101: with acute coronary syndromes, N Engl J Med, 2006;355: therapy for non–ST-segment elevation acute coronary syndromes:
2557–67. 2203–16. American College of Chest Physicians Evidence-Based Clinical
15. Cannon CP, Weintraub WS, Demopoulos LA, et al., Comparison of 32. Stone GW, Ware JH, Bertrand ME, et al., Antithrombotic strategies Practice Guidelines (8th Edition), Chest, 2008:670S–707S.
early invasive and conservative strategies in patients with unstable in patients with acute coronary syndromes undergoing early 49. Tricoci P, Peterson ED, Roe MT, et al., Patterns of guideline
coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor invasive management: one-year results from the ACUITY trial, adherence and care delivery for patients with unstable angina and
tirofiban, N Engl J Med, 2001;344:1879–87. JAMA, 2007;298:2497–2506. non-ST-segment elevation myocardial infarction (From the
16. Glaser R, Herrmann HC, Murphy SA, et al., Benefit of an early 22. The Fifth Organization to Assess Strategies in Acute Ischemic CRUSADE quality improvement initiative), Am J Cardiol, 2006;98:
invasive management strategy in women with acute coronary Syndromes Investigators, Comparison of fondaparinux and 30–35Q.
syndromes, JAMA, 2002;288:3124–9. enoxaparin in acute coronary syndromes, N Engl J Med, 50. Ohman EM, Roe MT, Smith SC, et al., Care of non-ST-segment
17. Mahoney EM, Jurkovitz CT, Chu H, et al., Cost and cost- 2006;354:1464–76. elevation patients: Insights from the CRUSADE national quality
effectiveness of an early invasive versus conservative strategy for 34. Mehta SR, Granger CB, Eikelboom JW, et al., Efficacy and safety of improvement initiative, Am Heart J, 2004;148:S34–9.
the treatment of unstable angina and non-ST-segment elevation fondaparinux versus enoxaparin in patients with acute coronary 51. Roe MT, Peterson ED, Newby LK, et al., The influence of risk status
myocardial infarction, JAMA, 2002;288:1851–8. syndromes undergoing percutaneous coronary intervention: results on guideline adherence for patients with non-ST-segment
18. FRISC II Investigators, Invasive compared with non-invasive from the OASIS-5 trial, J Am Coll Cardiol, 2007;50:1742–51. elevation acute coronary syndromes, Am Heart J, 2006;151:
treatment in unstable coronary-artery disease: FRISC II prospective 35. Ruggeri ZM, Platelets in atherothrombosis, Nature Med, 1205–13.
randomised multicentre study. FRagmin and Fast Revascularisation 2002;8:1227. 52. Yan AT, Yan RT, Tan M, et al., Management patterns in relation to
during InStability in Coronary artery disease Investigators, Lancet, 36. Antithrombotic Trialists’ Collaboration, Collaborative meta-analysis risk stratification among patient with non-ST elevation acute
1999;354:708–15. of randomised trials of antiplatelet therapy for prevention of coronary syndromes, Arch Intern Med, 2007;167:1009–16.
US CARDIOLOGY 21
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84